Xencor Management

Management criteria checks 3/4

Xencor's CEO is Bassil Dahiyat, appointed in Aug 1997, has a tenure of 27.75 years. total yearly compensation is $6.81M, comprised of 10.6% salary and 89.4% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth €2.01M. The average tenure of the management team and the board of directors is 2.3 years and 7.8 years respectively.

Key information

Bassil Dahiyat

Chief executive officer

US$6.8m

Total compensation

CEO salary percentage10.59%
CEO tenure27.8yrs
CEO ownership0.4%
Management average tenure2.3yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bassil Dahiyat's remuneration changed compared to Xencor's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$208m

Dec 31 2024US$7mUS$721k

-US$233m

Sep 30 2024n/an/a

-US$211m

Jun 30 2024n/an/a

-US$190m

Mar 31 2024n/an/a

-US$146m

Dec 31 2023US$8mUS$700k

-US$133m

Sep 30 2023n/an/a

-US$119m

Jun 30 2023n/an/a

-US$128m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$8mUS$670k

-US$55m

Sep 30 2022n/an/a

US$30m

Jun 30 2022n/an/a

US$22m

Mar 31 2022n/an/a

US$109m

Dec 31 2021US$5mUS$625k

US$83m

Sep 30 2021n/an/a

-US$4m

Jun 30 2021n/an/a

US$24m

Mar 31 2021n/an/a

-US$64m

Dec 31 2020US$4mUS$600k

-US$69m

Sep 30 2020n/an/a

-US$83m

Jun 30 2020n/an/a

-US$80m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$4mUS$567k

US$27m

Sep 30 2019n/an/a

US$36m

Jun 30 2019n/an/a

US$49m

Mar 31 2019n/an/a

US$39m

Dec 31 2018US$4mUS$550k

-US$70m

Compensation vs Market: Bassil's total compensation ($USD6.81M) is above average for companies of similar size in the German market ($USD825.85K).

Compensation vs Earnings: Bassil's compensation has been consistent with company performance over the past year.


CEO

Bassil Dahiyat (54 yo)

27.8yrs
Tenure
US$6,811,829
Compensation

Dr. Bassil I. Dahiyat, Ph D., Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. Dr. Dahiyat serves as an Independent Director at Terray Ther...


Leadership Team

NamePositionTenureCompensationOwnership
Bassil Dahiyat
Co-Founder27.8yrsUS$6.81m0.42%
€ 2.0m
Bart Cornelissen
Senior VP & CFO1.1yrsUS$3.86m0.016%
€ 74.8k
John Desjarlais
Executive VP of Research & Chief Scientific Officer10.8yrsUS$2.83m0.26%
€ 1.2m
Celia Eckert
Senior VP5.7yrsUS$1.97m0.041%
€ 195.4k
Nancy Valente
Executive VP & Chief Development Officer2yrsUS$2.87m0.032%
€ 153.1k
Charles Liles
Associate Director and Head of Corporate Communications & Investor Relationsno datano datano data
Jennifer Sandoz
Senior VIce President of Human Resources3.8yrsno datano data
Kirk Rosemark
Senior Vice President of Regulatory Affairs & Quality Assurance3.3yrsno datano data
Eric Kowack
Senior Vice President of Program Leadership & Alliance Management2.3yrsno datano data
Dane Leone
Executive VP & Chief Strategy Officer1.3yrsno datano data
Kenneth Hung
Senior Vice President of Clinical Development (Autoimmune)less than a yearno datano data
Rod Humerickhouse
Senior Vice President of Clinical Development (Oncology)less than a yearno datano data
2.3yrs
Average Tenure
56.5yo
Average Age

Experienced Management: XE9's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Bassil Dahiyat
Co-Founder27.8yrsUS$6.81m0.42%
€ 2.0m
Todd Simpson
Independent Directorless than a yearno datano data
Richard Ranieri
Independent Director7.4yrsUS$340.40k0.0035%
€ 16.7k
Alan Montgomery
lead Independent Director10.2yrsUS$372.90k0.0044%
€ 21.0k
Kevin Gorman
Independent Director8.1yrsUS$332.90k0.0034%
€ 16.0k
Jeffrey Ravetch
Member of Scientific Advisory Board15.9yrsno datano data
Ellen Feigal
Independent Director6.5yrsUS$338.40k0.0035%
€ 16.7k
Kurt Gustafson
Independent Director10.8yrsUS$336.90k0.0049%
€ 23.3k
Dagmar Rosa-Bjorkeson
Independent Director5.4yrsUS$339.90k0.0035%
€ 16.7k
Barbara Klencke
Independent Director1.7yrsUS$324.40k0%
€ 0
7.8yrs
Average Tenure
66.5yo
Average Age

Experienced Board: XE9's board of directors are considered experienced (7.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/25 10:19
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xencor, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Zhiqiang ShuBerenberg
Alec StranahanBofA Global Research